Latin America – Fixed-line, Internet and Broadband Statistics, New Report Launched

This Latin America – Fixed-line, Internet and Broadband Statistics report provides 469 tables and 118 charts illustrating the fixed-line, internet, broadband and digital economy/media sectors in Latin America and the Caribbean (LAC), both for individual countries and the region as a whole. Very brief summaries are given in some chapters, while the original documents should be accessed for full descriptions and commentary.

Improved international connectivity to herald cheaper internet access pricing into 2016

Market competition

In line with most other regions, the fixed-line market has been liberalised with the exception of Cuba and a few instances where the state has retained a significant interest in the incumbent operator. As the market has evolved, both in terms of the competitive environment and technologies available, a number of players have taken the opportunity to compete against established operators. VoIP has enabled new entrants to offer voice services while regulatory measures on Local Loop Unbundling (LLU) have for many years promoted competition with DSL access.

Although the incumbents continue to dominate the fixed-line sector, there have been notable regulatory moves to limit their dominance and so encourage competition. The key development in this regard is ongoing in Mexico, where América Móvil’s fixed-line division Telmex has a 75% market share of fixed lines. Legislative reform will compel Telmex to reduce its market share to below 50%. The reform is additionally aimed at reducing charges for consumers and businesses, and at upgrading and expanding telecoms infrastructure.

Alternative telcos have been able to establish themselves in a number of smaller markets where poor penetration of services and small populations provide limited potential for growth. In the Caribbean, the key players LIME and Digicel continue to dominate fixed-line access and internet services, though in these smaller markets scale is a key factor enabling them to invest in infrastructure.

International connectivity

During the last few years there have been significant investments made to develop regional fibre rings connecting national backbone networks. This has required the cooperation of a number of governments in affected countries, which have promoted regional strategies to improve connectivity for their citizens. In addition, new submarine cables are in development. A consortium is building the 40Tb/s South Atlantic Cable System (SACS) connecting Brazil to Angola, while a second link will connect Brazil to the US. Cuba’s connection to the internet via the ALBA-1 cable from Venezuela has enabled citizens’ access to a number of internet rooms for the first time.

Broadband

Given the range and size of the LAC region, there remain wide differences in broadband use among countries. While some including St Kitts & Nevis, Barbados, Trinidad & Tobago, Uruguay, Chile, Argentina, and Mexico have fixed broadband penetration ranging between 11% and 30%, others including Haiti, Paraguay, Nicaragua and Cuba have much lower penetration. This continues to be of concern to governments keen to develop infrastructure and promote online access in a bid to stimulate social inclusion and develop economic growth. In many markets fixed-line infrastructure remains poor and so teledensity is low. This has restricted the availability of DSL-based services in rural and underserved semi-urban areas, while fibre-based broadband remains largely confined to certain suburbs of the major cities.

Governments and regulators are addressing these shortcomings by promoting mobile broadband as a viable alternative. To this end a number of spectrum auctions have been held across the region, while still other auctions, particularly for spectrum in the digital dividend band, are anticipated in 2015 as analogue broadcasts are switched off and spectrum is reallocated for mobile data services. Much still needs to be done to address uncertainties related to spectrum refarming and licence renewals, and so secure time for operators to plan long-term investments and business strategies. Yet mobile broadband is now a central and increasingly important plank to the overall connectivity strategies of governments across the region.

Know more about this report at – http://mrr.cm/ZVQ

Find all Telecom Infrastructure and Networks Report at: http://www.marketresearchreports.com/telecom-infrastructure-networks

About Market Research Reports, Inc.

Market Research Reports, Inc. is the world’s leading source for market research reports and market data. We provide you with the latest market research reports on global markets, key industries, leading companies, new products and latest industry analysis & trends.

Type 1 Diabetes – Epidemiology Forecast to 2023, New Report Launched

Type 1 diabetes, formerly referred to as insulin-dependent diabetes, is a type of diabetes that predominantly develops in children or young adults before the age of 40 years. The condition, therefore, was also referred to as juvenile diabetes. Type 1 diabetes accounts for about 10% of all diabetes cases and occurs as a result of the autoimmune destruction of pancreatic beta cells, which are responsible for producing insulin – a hormone that regulates blood sugar. If the condition is left untreated, blood sugar levels accumulate. In addition to the pancreas, high levels of blood sugar can damage other major organs, such as the heart, blood vessels, nerves, eyes, and kidneys; such damage can be life threatening. Thus, type 1 diabetes has an immense impact on the physical, psychological, and social well-being of patients. Furthermore, research suggests that the incidence of type 1 diabetes is increasing globally, which may lead to an increased burden on healthcare resources (Holt et al., 2004; Mayo Clinic, 2014; WHO, 2013).

This report provides an overview of the risk factors, comorbidities, and the global and historical trends for type 1 diabetes in the eight major markets (8MM) (US, France, Germany, Italy, Spain, UK, Japan, and Canada). In addition, the report includes a 10-year epidemiological forecast for the diagnosed prevalent cases of type 1 diabetes segmented by age (ages 0–14 years,15–29 years, 30–44 years, 45–59 years, 60–74 years, and ≥75 years) and sex. Furthermore, the report provides the distribution of diagnosed prevalent cases of type 1 diabetes segmented by body mass index (BMI) (kg/m2) (BMI <20, BMI 20–<25, BMI 25–<30, BMI ≥30) in these markets.

According to Publisher’s analysis, the diagnosed prevalent cases of type 1 diabetes in the 8MM will grow by 40.40% over the next decade, from 6.02 million prevalent cases in 2013 to 8.45 million prevalent cases in 2023. Publisher epidemiologists attribute the increase in the diagnosed prevalent cases of type 1 diabetes in the 8MM to environmental factors (seasonal variation) coupled with genetic factors, such as a family history of type 1 diabetes. However, further research is necessary to clearly understand the epidemiological factors responsible for the growth in the prevalent cases of type 1 diabetes (Onkamo et al., 1999).

Spanning over 49 pages, “EpiCast Report: Type 1 Diabetes – Epidemiology Forecast to 2023” report covering the Introduction, Epidemiology, Appendix.

Know more about this report at – http://mrr.cm/ZVN

Find all Pharma and Healthcare Report at: http://www.marketresearchreports.com/pharma-healthcare

About Market Research Reports, Inc.

Market Research Reports, Inc. is the world’s leading source for market research reports and market data. We provide you with the latest market research reports on global markets, key industries, leading companies, new products and latest industry analysis & trends.

Irritable Bowel Syndrome – Epidemiology Forecast to 2023, New Report Launched

Irritable bowel syndrome (IBS) is a chronic, relapsing gastrointestinal disorder that is characterized by abdominal discomfort or pain, bloating, and changes in bowel habit. Due to the lack of a demonstrable structural abnormality to explain these symptoms, IBS is classified as a functional gastrointestinal disorder.

This report provides an overview of the risk factors, comorbidities, and global trends for IBS in the seven major markets (7MM) (US, France, Germany, Italy, Spain, UK, and Japan). It includes a 10-year epidemiological forecast for the total prevalent cases of IBS (diagnosed and undiagnosed) segmented by age (10–18 years, 19–34 years, 35–44 years, 45–54 years, 55–64 years, 65–74 years, 75–84 years, and ≥85 years), sex, and subclassification of predominant bowel habits (diarrhea-predominant IBS [IBS-D], constipation-predominant IBS [IBS-C], mixed presentation IBS [IBS-M], and unsubtyped IBS [IBS-U]) in these markets. For this analysis, Publisher epidemiologists defined IBS using the International Classification of Diseases, Tenth Revision (ICD-10) code for IBS (K58). Additionally, to construct the epidemiological forecast for the total prevalent cases of IBS in the 7MM, Publisher epidemiologists used country-specific studies that provided the total prevalence of IBS using the Rome II diagnostic criteria.The total prevalent cases of IBS includes men and women who may or may not have been formally diagnosed as having IBS, but have been identified as having IBS symptoms using the Rome II IBS diagnostic criteria (Thompson et al., 1999).

In 2013, there were 40,777,607 total prevalent cases of IBS in the 7MM. Publisher epidemiologists forecast that the total prevalent cases in the 7MM will increase to 42,366,389 by 2023, at an Annual Growth Rate (AGR) of 0.39%. All markets, except for Germany and Japan,will see a small increase in the number of cases at varying AGRs. Since Publisher epidemiologists held the prevalence constant throughout the forecast period, the differences observed in growth are driven by changes in the underlying population dynamics of each market.

Spanning over 49 pages, “EpiCast Report: Irritable Bowel Syndrome – Epidemiology Forecast to 2023” report covering the Introduction, Epidemiology, Appendix.

Know more about this report at – http://mrr.cm/ZVf

Find all Diseases Report at: http://www.marketresearchreports.com/diseases

About Market Research Reports, Inc.

Market Research Reports, Inc. is the world’s leading source for market research reports and market data. We provide you with the latest market research reports on global markets, key industries, leading companies, new products and latest industry analysis & trends.

Global Pharmaceutical Market Benchmark Report – Retrospective and Forward-Looking Analysis of the Leading Pharmaceutical Companies, New Report Launched

Pfizer was the Peer Group Benchmark Leader

According to Publisher’s proprietary benchmarking analysis, Pfizer was the Global Pharmaceutical Market Benchmark Leader in 2013 with an overall score of 6.22. Pfizer’s leadership status was the result of cost-cutting largely the headcount reductions from the divesture of its Animal Health business. This along with other rationalization measures, contributed to the company’s income growth, and helped to drive Pfizer’s net margin performance in 2013.

Pharmaceutical Market Beginning to Show Signs of Stability

According to Publisher’s Global Pharmaceutical Market Benchmark Report, the combined peer group revenue and average operating margin remained stable in 2013 when compared with 2012. Revenue from this peer group came in slightly lower by -0.2% to $718.7 billion. The average operating margin of the peer group was steady at 21.5%; however this was down by 90 basis points when compared to 2011. On the clinical side, R&D spending grew by $800 million to $111.9 billion in 2013, an increase of 0.7%.

J&J was the growth leader in absolute dollars, increasing by $4.1 billion in 2013 driven by the company’s immunology and oncology portfolios. Biogen Idec was the peer group revenue growth leader in 2013. Biogen’s sales increased to $5.5 billion in 2013, a 25.7% rise from the $4.2 billion the company reported in 2012. Revenues soared as a result of Tysabri (natalizumab), the company’s injectable monotherapy for treating relapsing forms of multiple sclerosis (MS), and the new oral MS drug Tecfidera (dimethyl fumarate). Sales of Tysabri grew 36.4% year-to-year from $1.1 billion in 2012 to $1.5 billion in 2013. The company also benefited from recognizing $876.1 million in new revenues from sales of Tecfidera despite having only been approved in March of 2013.

Peer Group R&D Spending

The growth in peer group R&D spending was largely the result of the industry’s top spenders, Roche, Novartis and J&J. Roche was the R&D spending leader in 2013, outlaying almost $10 billion in the clinic, representing 19.8% of the company’s total sales. Roche’s R&D spending was bolstered by continued investments in oncology and neuroscience therapeutic areas such as the company’s investigational anti-PD-L1 antibody targeting lung cancer, and the advancement of its programs for Alzheimer’s disease. Meanwhile, Novartis, and J&J each added about $500 million to their respective clinics. Novartis’ R&D spending grew by 5.6% to $9.9 billion and J&J spent $8.2 billion, which was up 6.8% when compared to the same period in 2012.

In efforts to improve margins, cost-cutting remained a strategic necessity for some companies. Pfizer shaved over $1.2 billion in R&D spend and Merck cut over $600 million in its clinical operations. In addition, the companies’ reduced their workforces to help stabilize profits in the aftermath of their patent losses.

FDA Approvals Drive Much Needed Value in the Sector

While the 27 NME approvals by the FDA in 2013 were below the 39 seen in 2012 — the highest number of NME approvals since 1997 — at least 15 of the 2013 arrivals are expected to achieve blockbuster status by 2019. This is four more than the 11 drugs the FDA approved in 2012 expected to attain blockbuster sales. Consequently, the value added by the new therapies that gained FDA approval in 2013 far exceeds that of 2012’s approvals, despite there being 12 fewer NMEs approved.

The year 2013 will go down as one of the most prolific in the industry, not necessarily in terms of the number of new drug approvals, but almost certainly in terms of the underlying value added by this new wave of therapies. Of the 27 NMEs approved by the FDA in 2013, more than half are expected each to achieve worldwide blockbuster status, with the total revenues for this group of assets estimated to reach more than $55 billion by 2019. What is particularly astonishing is that the revenue this group of assets is expected to achieve is almost entirely attributable to three new therapies: Gilead’s Sovaldi, Biogen’s Tecfidera, and J&J’s Olysio.

Patent Cliff to Erode $65B in Sales by 2019

Publisher estimates the patent cliff will erase approximately $65 billion in sales through 2019 as some of the top-selling drugs lose patent exclusivity. The drug makers that will be hardest hit will include Otsuka, GSK, Eli Lilly, and AstraZeneca. Otsuka’s anti-psychotic drug Abilify (aripiprazole) which it co-markets with BMS will lose $6.2 billion by 2019 as the result of generic competition. Similarly, GSK’s Advair will see its sales plummet by $4.8 billion in the same time frame.

Deal Values Soar Due to Shire Acquisition

The total number of deals (M&A and licensing) in the pharmaceutical market fell slightly from 1,494 in 2012 to 1,483 in 2013. While both years were down by about 300 deals from 2011 (1,800), the total deal value across M&A and licensing has remained very stable at about $85 billion over the past three years. Moving ahead through the rest of CY2014, the total deal value jumps significantly to around $135 billion through the end of July, which takes into account AbbVie’s $54 billion megamerger with Shire. While the total deal value has already eclipsed those of previous four years, Publisher expects the number of deals in 2014 will fall short of historical averages.

In total dollar terms, AbbVie’s acquisition of Shire is valued at approximately $53 billion, making it the sixth largest merger in the history of the pharmaceutical industry. AbbVie’s rationale for this deal consists of a mix of portfolio diversification, cost synergies, tax savings, and the lowering of the company’s dependency on Humira (adalimumab) for generating sales. Clearly, AbbVie is targeting Shire’s marketed drug portfolio which includes therapies in CNS, rare diseases and gastrointestinal disorders. The graph below shows Publisher’s Net Present Value (NPV) analysis of Shire’s leading assets.

AstraZeneca Rejects Pfizer’s Takeover Offer

As the May 26 deadline passed to begin negotiations, AstraZeneca rejected Pfizer’s third takeover bid for the UK drugmaker. AZ’s board turned down Pfizer’s final offer of roughly $120 billion, or $92.48 per share, with a 45% cash component citing that Pfizer’s proposal significantly undervalued the company and its prospects. In addition to believing that Pfizer’s offer was too low, AstraZeneca had grave concerns about Pfizer’s post-acquisition track record, and its inversion strategy. Pfizer stated that if it had purchased AZ, it would change its domicile to the relatively tax-friendly UK – which would inevitably mean cuts to AZ’s business in the US. AstraZeneca only had to look at Pfizer’s recent past as an example. When Pfizer bought Wyeth in 2009, it slashed over $4 billion in costs and cut payroll by almost 20,000 – the majority of which fell on legacy Wyeth operations. AstraZeneca had little reason to expect anything different this time around.

CNS Franchise: A Fragmented Market Exposed to Generics

The CNS market remains fragmented. Some pockets within the CNS franchise have been met with clinical development and investment into specific neurological conditions such as multiple sclerosis, and schizophrenia. However, others areas such as Parkinson’s and Alzheimer’s diseases have seen a lack of new market competition and novel treatment approaches. Many drug makers have abandoned their research efforts into these disorders in search of areas with greater return-on-investment, and more commercial viability. Publisher estimates that the peer group CNS market remained relatively flat in 2013, rising by only 2.2% to approximately $69 billion.

Pfizer is the leader in the CNS franchise, commanding about 12% of the CNS market. Pfizer’s strong position is largely the result of its anticonvulsant drug Lyrica (pregabalin) which posted $4.8 billion in sales in 2013 and is one of the top-selling drugs in the franchise.

Conversely, companies such as Eli Lilly and AstraZeneca have lost share of the CNS market since 2010. Eli Lilly’s share fell mainly from the decrease in sales of Zyprexa (olanzapine) Lilly’s dopamine antagonist used to treat schizophrenia, and bipolar disorder. Back in 2010, sales from Zyprexa were over $5 billion. However, in 2013, Zyprexa sales have plummeted to $1.2 billion as a result of the drug losing its US patent exclusivity in 2011. Meanwhile, AZ has given up the greatest share of the CNS market over the past three years. AZ’s CNS segment has been bleeding sales as a result of the company losing its patent on Seroquel (quetiapine fumarate), another treatment for bipolar disorder. This has led to the entry of cheaper generic alternatives from Teva, and Sandoz.

Regeneron’s Eylea Will Be the Top-Selling Eye Drug by 2016

In November of 2011, Regeneron shook-up the ophthalmology market when the FDA approved Eylea (afilibercept) for treating wet-AMD. Since then, Eylea has been beating analyst estimates and has gone on to reach blockbuster status representing one of the most successful drug launches by a biotechnology company. In 2013, sales of Eylea surged to over $1.4 billion, a 68.1% year-to-year increase from $838 million in 2012. Regeneron has been driving the market penetration for Eylea by expanding the drug’s territory coverage to include Japan, Australia, Colombia, Brazil and the UK, and its treatment label to comprise other disease of the eye, such as diabetic macular edema, and branch/central retinal vein occlusion.

One of the key drivers behind the success of Eylea is patients switching to the drug from Lucentis (ranbizumab), and off-label Avastin. Results from Regeneron’s two Phase III trials, VIEW 1, and VIEW 2 demonstrated that Eylea was non-inferior to ranbizumab at maintaining visual acuity, and there was no drop-off associated with less frequent dosing. Publisher expects the less frequent dosing schedule has led to a decrease in office visits, and therefore fewer IVT injections which has driven patients’ switching behavior, therefore, and helped to fuel Eylea sales.

Pipeline Highlight: Amgen Delivers First-Ever Ph. III Data on New Class of PCSK9 Drugs

Amgen announced data from its Phase III TESLA trial evaluating evolocumab (formerly, AMG-145) met its primary endpoint of percent reduction from baseline in LDL-C. Evolocumab is an investigational fully human monoclonal antibody that inhibits PCSK9, a protein that reduces the liver’s ability to remove LDL-C, or “bad cholesterol” from the blood. TESLA was a two-part Phase II/III trial evaluating evolocumab in patients with homozygous familial hypercholesterolemia (HoFH), a rare and serious genetic disorder characterized by severely elevated LDL-C at an early age. HoFH occurs in approximately one in a million individuals, who have two altered copies of a cholesterol-regulating gene that result in absent or defective LDL receptor function. HoFH can cause a four-fold increase in LDL-C levels.

If successful, Amgen will be first to market in this new category of cardio medicines with a regulatory filing expected by the end of this year. However, Amgen is not alone in the PCSK9 class. Regeneron and Sanofi are moving forward with their drug alirocumab, while Pfizer’s bococizumab remains a respectable third runner. In the aggregate, these three drugs will create at least a $10 billion market opportunity with each drug fixed to hit $3.5 billion in peak sales. Being first-to-market might not be beneficial to Amgen as payers and pharmacy benefit managers are concerned about the cost of treatment running as high as $1,500 per prescription. Many patients with hard-to-control cholesterol are taking cheap generic statins; the majority of them could be moved to the biologic therapy resulting in staggering cost to the healthcare system given that there are some 70 million patients with high cholesterol.

Know more about this report at – http://mrr.cm/ZVx

Find all Healthcare Report at: http://www.marketresearchreports.com/healthcare

About Market Research Reports, Inc.

Market Research Reports, Inc. is the world’s leading source for market research reports and market data. We provide you with the latest market research reports on global markets, key industries, leading companies, new products and latest industry analysis & trends.

Global Beer Trends Report 2014, New Report Launched

The 2014 Global Beer Trends Report covers historical and forecast global beer consumption trends, production, imports and exports data across 168 markets worldwide.

The report is numbers based and available exclusively in Excel, allowing easier interrogation and manipulation of data.

Key Findings

  • Global beer production rises again
  • USA remains leading importer
  • China remains leading beer consumer

Synopsis

A detailed picture of the world beer market in an easily digestible format.

Reasons to Buy

The 2014 Global Beer Trends Report is an essential guide for both brewers and analysts worldwide. The data horizon covers 2008-2013, plus forecasts to 2019. All data has been researched by experienced ‘on the ground’ analysts, who have an ongoing dialogue with the industry

Spanning over 136 pages, “Global Beer Trends Report 2014” report covered companies are – A-BInBev, Heineken, SABMiller, China Resources Enterprises, Carlsberg Group, Tsingtao, Molson Coors Brewing Company, Modelo, Yanjing Brewery, Kirin Group, Efes Beverage Group, Asahi Breweries, Castel, Chongqing Brewery, Constellation Brands, USA, Henan Jinxing Brewery, Diageo PLC, UK, San Miguel Corporation, Philippines, Polar, Cervejaria Petropolis, Suntory Holdings, Saigon Brewery

Know more about this report at – http://mrr.cm/ZVg

Find all Food and Beverages Report at: http://www.marketresearchreports.com/food-beverages

About Market Research Reports, Inc.

Market Research Reports, Inc. is the world’s leading source for market research reports and market data. We provide you with the latest market research reports on global markets, key industries, leading companies, new products and latest industry analysis & trends.

Cushing’s Syndrome – Epidemiology Forecast to 2023, New Report Launched

Cushing’s syndrome (CS) is a rare disorder caused by prolonged exposure to excess amounts of circulating free glucocorticoids, such as cortisol. Cortisol is a hormone produced by the adrenal glands that has many functions in the body, such as anti-inflammatory action, antiallergic action, antianabolic action, and amino acid catabolic action (Resmini, 2014). CS is associated with increased mortality caused by complications due to excess cortisol (Resmini, 2014). This epidemiological analysis focuses on CS, and four subtypes of CS: Cushing’s disease, ectopic-adrenocorticotropic hormone (ACTH) CS, adrenal adenoma CS, and adrenal carcinoma CS.

This report provides an overview of the risk factors, comorbidities, and the global and historical epidemiological trends for CS in the six major markets (6MM) (US, France, Germany, Italy, Spain, and UK). The report also includes a 10-year epidemiological forecast for the diagnosed prevalent cases of CS, Cushing’s disease, ectopic ACTH CS, adrenal adenoma CS, and adrenal carcinoma CS segmented by age (18 to ≥85 years) and sex in these markets. Additionally, Publisher epidemiologists provide the immediate outcome of transsphenoidal adenomectomy surgery (TSS) in patients with Cushing’s disease.

For this analysis, Publisher epidemiologists used data available from Orphanet to construct the 10-year epidemiological forecast for the diagnosed prevalent cases of Cushing’s disease, ectopic ACTH CS, adrenal adenoma CS, and adrenal carcinoma CS in the 6MM.

Publisher epidemiologists forecast an increase in the diagnosed prevalent cases of CS in the 6MM, from 32,634 diagnosed prevalent cases in 2013 to 34,573 diagnosed prevalent cases in 2023, with an annual growth rate (AGR) of 0.59%. In 2023, the US will have the highest number of diagnosed prevalent cases of CS, with 17,162 diagnosed prevalent cases. Additionally, each of the 6MM will see an increase in diagnosed prevalent cases over the 10-year forecast period, except for Germany, which will have a negative AGR of 0.14%. Because Publisher epidemiologists applied a constant diagnosed prevalence in each of the 6MM, the trends in the diagnosed prevalent cases of CS are attributed to changing population demographics in the 6MM.

Spanning over 58 pages, “EpiCast Report: Cushing’s Syndrome – Epidemiology Forecast to 2023” report covering the Introduction, Epidemiology, Appendix.

Know more about this report at – http://mrr.cm/ZVY

Find all Pharma and Healthcare Report at: http://www.marketresearchreports.com/pharma-healthcare

About Market Research Reports, Inc.

Market Research Reports, Inc. is the world’s leading source for market research reports and market data. We provide you with the latest market research reports on global markets, key industries, leading companies, new products and latest industry analysis & trends.

Australia – Telco Company Profiles – 2nd Tier, New Report Launched

This report provides an overview of the main 2nd tier telcos in Australia, including key revenue an operational data as well an analysis on company strategies in response to market developments and an intensifying competitive environment.

The companies profiled in this report are Amcom Telecommunications, iiNet Limited, Macquarie Telecom, M2 Telecommunications, AAPT (acquired by TPG in early 2014 though operated as a separate business), Nextgen Networks (Nextgen Group), TPG Telecom and FOXTEL.

There is a separate report that covers: Telstra, Optus and Vodafone.

Solid performances among operators auger well for the NBN age

Operators in this market reported steady revenue growth in fiscal 2014, reflecting an encouraging ongoing trend. The exception was AAPT, though this company has now been acquired by TPG and so a new era for the company may herald a change in its fortunes as it is able to utilise its assets in line with TPG’s wholesale services strategy. This acquisition showcased that in the market prepped for the NBN these players require size, geographic reach and a significant customer base among the lucrative government and business segments. This scale has enabled these 2nd tier players to weather aggressive competition from Telstra, which has itself firmed up its relationship with FOXTEL through a wholesale arrangement, enabling FOXTEL to provide broadband and voice services through Telstra’s infrastructure.

There are many transformations yet expected in the telecom sector in coming years as the market adjusts to the NBN. NBN Co, operating under a multi-technology platform rather than the FttP architecture originally envisaged, has shown a reinvigorated purpose in recent months which should see an escalation in the number of connected premises. Given these developments, many opportunities yet remain for the 2nd tier players, as TPG has shown with its commitment to fibre-enable up to half a million apartments within its existing footprint.

Amcom

Amcom provides a range of services bases on fibre and DSL infrastructure. It also offers training services to the consumer, corporate, wholesale, government and SME markets. The Western Australia-based company has solid prospects for future growth, and remains a well-managed and focused business. Amcom has constructed over 2,000km of high-speed fibre optic networks in Perth, Darwin, Alice Springs and Adelaide. It has seven data centres in its own right, while its network connects to 71 centres in the capital cities. The network provides access to around 80% of business premises in these cities. The company in mid-2014 announced plans to make acquisitions on the East Coast to further develop its Cisco-based platform. The company has shown consistent revenue growth in recent years, while its strategy for future growth appears promising.

AAPT

AAPT was acquired in 1999 by Telecom New Zealand as it made a $2 billion bid to break into the Australian market. The investment proved to be unsound for Telecom’s shareholders, and in recent years AATP’s financial performance has deteriorated. Its key retail division was sold to iiNet in 2010, while its remaining business and wholesale interests were sold TPG in early 2014. Though owned by TPG, AAPT remains a separate business and manages a substantial interstate network including 11,000km of fibre, its own data centres in major capital cities, fibre and Ethernet infrastructure. It is also a partner with NBN Co. The company has undergone significant management changes as it struggles to revitalise its financial position, which will help TPG better absorb the company’s assets and manage its strategic position in a fast-changing market.

iiNet

iiNet has developed into one of the largest DSL providers in Australia. The company delivers a wide range of telecom services including fixed-voice, mobile and broadband, business data housing and cloud-based services, VoIP and IPTV. The company manages a significant DSL and FttP network. During the last few years iiNet has expanded through a strategic program of acquisitions, which has consolidated its strengthening market position in the business broadband and mobile voice and data sectors. In March 2014 the founder of iiNet, Michael Malone, stepped down as both CEO and chairman of the company after more than twenty years at the helm. The company will enter a new phase of development with a new CEO. The company’s financials have been solid for a number of years, while growth at 7% for FY2014 enabled to company to broach $1 billion in revenue for the first time.

Macquarie Telecom

Established in 1992, Macquarie Telecom was one of the first telcos of the deregulated era. Its two key target markets are Australian mid-size corporates and the government sector. The Hosting business continues to be a key growth platform. With a third data centre operational in mid-2013, the company has bolstered its hosting and cloud-based services, which remain the main focus of its strategy for growth.

TPG Telecom

TPG Telecom provides a range of telecom services and also owns a cloud-hosting company and the PIPE network infrastructure. The company is delivering an extensive FttB service to apartment buildings in capital cities. In late 2014 these plans were approved by the AAAC, which determined that the FttB networks would not go against the level playing field provisions within the Telecommunications Act. TPG has also secured spectrum in the 2.5GHz band to bolster its wireless broadband capabilities, and has committed to investing in additional capacity with a subsea cable linking to New Zealand and the US West Coast. TPG’s capabilities and reach were enhanced following its $450 million acquisition of AAPT’s wholesale and business services from Telecom New Zealand, completed in February 2014.

Nextgen Networks

Nextgen specialises in data services for carriers, service providers, government and corporations. It owns and operates one of Australia’s largest national fibre networks, of over 19,000km of fibre rings, as well a data centres in all capital cities. Nextgen has rolled out around 6,000km of a fibre backhaul link to Darwin, which it manages on behalf of NBN Co as part of the Regional Backbone Blackspots Program. The Perth-Singapore submarine cable, being managed by Nextgen’s subsidiary ASC International, secured landing permits in early 2014, so enabling the operator to proceed with the construction phase.

FOXTEL

FOXTEL is the largest subscription TV (STV) provider in Australia, offering over 200 viewing channels. National coverage was secured in 2012 following the company’s acquisition of AUSTAR. Company ownership is equally divided between Telstra and News Corporation. More than 2.6 million homes had an STV service from FOXTEL in mid-2014, showing a 5.6% growth in subscriber numbers year-on-year. The company hopes to expand its services with a triple-play bundle of TV, broadband and telephony service during the first quarter of 2015, with the latter two services resulting from a wholesale agreement with Telstra.

M2 telecommunications

M2 has shown consistent growth since the mid-2000s, both through organic growth and strategic acquisitions. In 2009 it acquired People Telecom and the business assets of Commander Communications, both at bargain prices. In 2010 the company completed the acquisition of selected business assets of Clever Communications and Bell Networks, while in 2011 it purchased Clear Telecoms and later the subscribers and assets of AUSTAR Mobile from the pay TV satellite provider. In 2012 the assets of Primus Telecommunications were acquired adding further to its subscriber base. Further acquisitions in 2013 brought in Dodo and Eftel under the M2 umbrella. M2 has since declared that it may invest further in the energy sector, taking advantage of deregulated markets and the low customer acquisition cost advantages held by Dodo Energy.

Spanning over 119 pages, “Australia – Telco Company Profiles – 2nd Tier” report covering the Telecoms Market Revenue Overview, AAPT, Amcom Telecommunications Limited, Foxtel, iiNet, Macquarie Telecom, M2 Telecommunications, Nextgen Networks Pty Limited, TPG Telecom, Wholesale Aggregators.

Know more about this report at – http://mrr.cm/ZVM

Find all Telecom Report at: http://www.marketresearchreports.com/telecom

About Market Research Reports, Inc.

Market Research Reports, Inc. is the world’s leading source for market research reports and market data. We provide you with the latest market research reports on global markets, key industries, leading companies, new products and latest industry analysis & trends.

Alzheimer’s Disease – Pipeline Review, H1 2014, New Report Launched

Alzheimer’s Disease – Pipeline Review, H1 2014 report provides an overview of the Alzheimer’s Disease’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Alzheimer’s Disease, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases.

It also reviews key players involved in the therapeutic development for Alzheimer’s Disease and special features on late-stage and discontinued projects.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Alzheimer’s Disease
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Alzheimer’s Disease and enlists all their major and minor projects
  • A review of the Alzheimer’s Disease products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • Coverage of the Alzheimer’s Disease pipeline on the basis of target, MoA, route of administration and molecule type.

Spanning over 1242 pages, “Alzheimer’s Disease – Pipeline Review, H1 2014” report covering the Introduction, Alzheimer’s Disease Overview, Therapeutics Development, Drug Profiles, Appendix. The report covered few companies are – Bristol-Myers Squibb Company, Johnson & Johnson, Boehringer Ingelheim GmbH, F. Hoffmann-La Roche Ltd., Biogen Idec Inc., OXIS International, Inc., Shionogi & Co., Ltd., NsGene A/S, Amgen Inc., Sanofi

Know more about this report at – http://mrr.cm/ZVd

About Market Research Reports, Inc.

Market Research Reports, Inc. is the world’s leading source for market research reports and market data. We provide you with the latest market research reports on global markets, key industries, leading companies, new products and latest industry analysis & trends.